Scinai Immunotherapeutics Turns Financial Corner with $4.8 Million Net Gain
Biotechnology company Scinai Immunotherapeutics reports a significant financial turnaround in 2024, transforming a previous year's loss into a net gain through strategic financial management and early revenue generation.
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology treatments, has achieved a notable financial improvement in 2024, reporting a $4.8 million net gain compared to a $6.5 million loss in 2023.
The company's financial recovery was primarily driven by a $14.8 million financial income resulting from a loan-to-equity conversion. This strategic financial maneuver significantly contributed to the company's positive financial outlook.
In a milestone achievement, Scinai generated its first-ever revenue of $658,000 from its Contract Development and Manufacturing Organization (CDMO) unit. This initial revenue stream represents a potential new growth avenue for the company.
Research and development expenses remained consistent at $5.6 million, while general and administrative costs decreased to $2.6 million. At the end of the year, the company maintained cash and equivalents totaling $1.9 million.
The financial results suggest Scinai is making strategic progress in stabilizing its financial position while continuing to develop its inflammation and immunology therapeutic pipeline and expand its CDMO services.